Hikma Pharmaceuticals Plc · LSE:HIK
Hikma Pharmaceuticals — Technical Presentation (November 2022)
15 slides from Hikma Pharmaceuticals's technical presentation, November 2022
Slide 1: Hikma Injectables Portugal site visit – November 2022
Better health. Within reach. Every day. Hikma Injectables Portugal site visit – November 2022
Slide 2: Introduction – Injectables is central to Hikma's value creation thesis
Introduction – Injectables is central to Hikma’s value creation thesis A unique, global platform Strategic initiatives to diversify Strong and sustainable • Strong market positions across portfolio and drive continued platform for future growth US, Europe and MENA progress • Pipeline delivering 10 t
Slide 3: The Injectables business today
The Injectables business today Hikma’s largest > $1B in revenues business segment: since 2021 Injectables 10 Year Revenue CAGR of 13% delivering sustainable long-term growth 2021 Core operating margin consistently revenue 41% above 37% since 2014 Top 3 generic Injectables manufacturer in the US (by
Slide 4: History of organic and acquisitive growth
History of organic and acquisitive growth (million) Cherry Hill • Acquired Custopharm Portugal Dayton MENA • Acquired Teligent’s Core revenue • Pre-filled Compounding $1,200 Acquired syringes Expansion High-containment Canadian Assets Core operating profit Bedford Labs facility facility Portugal of
Slide 5: US - A top supplier with opportunities ahead
US - A top supplier with opportunities ahead US generic injectables market share by volume1 Multiple levers for North America growth Pfizer Strengthened US R&D team to Business development to Pfizer continue developing pipeline to augment portfolio with niche Top three launch 10-15 products each spe
Slide 6: MENA – Growing market share in growing markets
MENA – Growing market share in growing markets Overview of markets MENA strategy ($bn) 3.8 KSA 3.0 1.7 Egypt Focusing on larger markets Building a pipeline of 1.4 where we can leverage existing differentiated products through 1.6 expertise across the region targeted R&D effort UAE while benefitting
Slide 7: Europe - large market, local presence and our growth ambition
Europe - large market, local presence and our growth ambition A fragmented $7.5bn market – benefitting from local presence and alleviating shortages 2021 Injectable USD$ by country1,2 - generics 2021 Injectable sales by supplier2 - generics (in millions) (in millions) Currently operating New markets
Slide 8: Our Global operations
Our Global operations Plants and expansion plans
Slide 9: Our global footprint is growing as we invest for capacity and expanded capabilities
Our global footprint is growing as we invest for capacity and expanded capabilities to support future growth plans Injectables Manufacturing sites Germany Spending Italy Cherry Hill c.$45m+ Portugal Dayton annually on Injectables Jordan Morocco capex Algeria Egypt KSA Operating & Expanding Operating
Slide 10: Our global manufacturing capabilities
Our global manufacturing capabilities Geographic spread, local capacity and flexible production enable us to respond to evolving customer needs US Portugal Italy Germany Egypt Significant vial capacity and Controlled substance capabilities in localised ampoule capabilities the US for the US, with ad
Slide 11: Hikma Farmacêutica Portugal – Who we are
Hikma Farmacêutica Portugal – Who we are Our site today Notable facts past and present Hikma 4 Hikma 3 • High Containment Lyo/Liqs • Central Warehouse • #1 exporter of finished pharmaceutical products • QC Laboratories • Future Packaging in Portugal • Hikma´s injectable hub supporting our markets wo
Slide 12: Portugal expansion past and future
Portugal expansion past and future Hikma 1 – Liquids, lyos and admin 1992-2016 Hikma 2 - Cephalosporins 3 2 5 1 2 3 4 8 9 10 1 7 Hikma 4 – High containment 2016 - 2021 Hikma 3 – Central warehouse Hikma 5 – Production & Packaging 2021- 2025 Hikma 6 – Mixed use Hikma 7 - Warehousing Aseptic Bag fillin
Slide 13: Portugal Site Visit Conclusion
Portugal Site Visit Conclusion
Slide 14: Injectables – grow our leading position
Injectables – grow our leading position by expanding differentiated portfolio, entering adjacencies and leveraging high-quality manufacturing expertise Our Strategy: Deliver more from Build a portfolio that Inspire and enable 3 pillars of growth a strong foundation anticipates future health our peop
Slide 15: hikma.
hikma.
Hikma Pharmaceuticals — Technical Presentation (November 2022) on 6ix